The therapeutic potential of the DNA ligase IV inhibitor should need further validation on thyroid cancer cell lines characterized by different cancer genetic drivers (e.g. BRAF p.V600, NRAS p.Q61K) (29). This evidence concerns the gene BRAF and thyroid gland carcinoma.